Sickle Cell Treatment Demonstration Program

The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with si

The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).

Eligible entities include, Federally-qualified health center, as defined in section 1905(10(2)(B) of the Social Security Act (42 U.S.C. 1396d(10(2)(B), nonprofit hospital or clinic, or university health center that provides primary health care, that: (1) has a collaborative agreement with a community-based Sickle Cell Disease organization or a nonprofit entity with experience in working with individuals who have Sickle Cell Disease; and (2) demonstrates that either the Federally-qualified health center, the nonprofit hospital or clinic, the university health center, the community-based Sickle Cell Disease organization or the Sickle Cell Disease experts who serve as consultants to the project have at least 5 years of experience in working with individuals who have Sickle Cell Disease.

Specialized group (e.g. health professionals, students, veterans), Health Professional, Physically Afflicted (e.g. TB, Arthritis, Heart Disease), Public nonprofit institution/organization Projects will benefit individuals with Sickle Cell Disease and health professionals who provide care for individuals with Sickle Cell Disease.

All funds granted should be expended solely for carrying out the approved projects in accordance with Section 712 of the Public Law 103-357.

All funds granted should be expended solely for carrying out the approved projects in accordance with Section 712 of the Public Law 103-357.

Refer to the notice of funding opportunity (NOFO). Awards are made annually, in accordance with the project period method of awarding grants.

An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.

Evaluation criteria vary based on the grant/cooperative agreement program. Refer to criteria included in the notice of funding opportunity for each specific program.

All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. Notification is made in writing by a Notice of Award.

Final decisions are made 4 to 6 months after receipt of applications.

Competitive awards are typically made for up to 2 to 5 years, subject to the availability of funds. After initial awards, annual noncompetitive awards may be made contingent upon the submission of noncompetitive applications/progress reports and availability of funds and a determination that continued funding would be in the best interest of the federal government.